Amgen’s rare-disease treatment biosimilar Bkemv gets FDA approval
Pharmaceutical regulators approved Amgen’s AMGN, -1.27% Bkemv, a biosimilar to rare-disease treatment Soliris. The Food and Drug Administration said Tuesday that Bkemv, a monoclonal antibody ...